Format
Sort by

Send to

Choose Destination

Links from Books

Items: 13

1.

Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.

Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier WR Jr, Koch CJ.

Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):259-66. Epub 2002 Nov 23.

PMID:
12552344
2.

Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent.

Yamamoto F, Aoki M, Furusawa Y, Ando K, Kuwabara Y, Masuda K, Sasaki S, Maeda M.

Biol Pharm Bull. 2002 May;25(5):616-21.

3.
4.

[18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.

Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV.

Appl Radiat Isot. 2001 Jan;54(1):73-80.

PMID:
11144255
5.

Detection of hypoxia in human squamous cell carcinoma by EF5 binding.

Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, Mirza N, Morgan M, Rubin S, McKenna WG, Lord EM, Koch CJ.

Cancer Res. 2000 Apr 1;60(7):2018-24.

6.

Synthesis of new hypoxia markers EF1 and [18F]-EF1.

Kachur AV, Dolbier WR Jr, Evans SM, Shiue CY, Shiue GG, Skov KA, Baird IR, James BR, Li AR, Roche A, Koch CJ.

Appl Radiat Isot. 1999 Dec;51(6):643-50.

PMID:
10581679
7.

Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.

Rasey JS, Hofstrand PD, Chin LK, Tewson TJ.

J Nucl Med. 1999 Jun;40(6):1072-9.

8.

Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.

Hodgkiss RJ.

Anticancer Drug Des. 1998 Sep;13(6):687-702. Review.

PMID:
9755725
9.

Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.

Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, Koch CJ.

J Pharmacol Exp Ther. 1996 May;277(2):1049-57.

PMID:
8627516
10.

2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.

Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ.

Cancer Res. 1996 Jan 15;56(2):405-11.

11.

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA.

Radiology. 1995 Mar;194(3):795-800.

PMID:
7862981
12.

Nitroimidazoles and imaging hypoxia.

Nunn A, Linder K, Strauss HW.

Eur J Nucl Med. 1995 Mar;22(3):265-80. Review.

PMID:
7789400
13.
Items per page

Supplemental Content

Write to the Help Desk